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Tuberculosis (TB) is believed to affect around 10 million people worldwide. Treatment for TB 3 
includes isoniazid and rifampicin, with fixed-dose combination (FDC) recommended for improved 4 
patient compliance. Similarly, orally disintegrating tablets (ODTs) are an increasingly popular 5 
dosage form that aid compliance since they do not require swallowing. In this study ODTs of 6 
isoniazid and rifampicin, either as discrete or FDC doses, were formulated and bioequivalence 7 
between single and combination doses compared using in vitro and in silico approaches. 8 
Dissolution profiles were compared using FDA advised difference (f1) and similarity (f2) testing in 9 
biorelevant media. Rifampicin release from FDCs decreased by approximately 15% in fed-state 10 
media (failed f1 and f2), which was attributed to enhanced rifampicin degradation in the presence 11 
of isoniazid at lower pH. Apparent permeability (Papp) values derived from Caco-2 transport studies 12 
were included alongside dissolution results into a physiologically based pharmacokinetic (PBPK) 13 
model, to simulate in vivo bioavailability in healthy subjects. Models showed no difference in 14 
bioavailability between formulations or dosing (fasted or fed) state, despite the failures in 15 
dissolution-based bioequivalence testing, highlighting shortcomings in f1 and f2 assessment and 16 










Recognised as one of humankind’s oldest diseases, with evidence of cases dating back more than 2 
5000 years 1, tuberculosis (TB) remains a major cause of morbidity and mortality. Today there are 3 
an estimated 9.6 million TB cases worldwide, with the disease claiming 1.5 million deaths in 2014 4 
alone 2. Since 2000 the incidence of TB has fallen by 18%, at an average rate of 1.5% per year, 5 
with effective treatment within this time frame saving an estimated 43 million lives 2. 6 
 7 
TB is an infectious disease caused by the aerobic bacterium Mycobacterium tuberculosis (MTB). 8 
Transmission occurs through aerosolisation of the bacterium into droplet nuclei by coughing, 9 
sneezing or talking 3. Inhalation of the organism into the alveoli leads to respiratory infection, that 10 
if spreads, causes extrapulmonary tuberculosis, which can involve any organ system in the body 11 
4. Pulmonary tuberculosis, the most common presentation, is avoided in most cases of exposure 12 
through mucociliary clearance 5, or failing that through the successful activity of phagocytic 13 
alveolar macrophages, resulting in symptomless latent tuberculosis 6. Around 5% of TB infections 14 
progress to the active form of the disease within two years, with about 10% of latent cases 15 
reactivating at some point later in life 3.  TB outcome is dependent on a multitude of factors, most 16 
prominent of which is the immunocompetence of the individual, which itself depends on various 17 
intrinsic and extrinsic factors such as the hosts genetics and nutritional state, respectively 7,8.  18 
 19 
Clinical manifestation of TB depends on the site of infection. Pulmonary TB, historically referred 20 
to as consumption or pthisis, classically manifests as severe wasting 8, as well as cough, 21 
haemoptysis, chest pain, dyspnoea, malaise, fatigue, low-level fever and night sweats 9.  22 
Extrapulmonary TB can include the same symptoms as pulmonary TB, with a wide range of 23 
additional symptoms based upon the site of infection, such as meningitis (CNS), lymphadenitis 24 
(lymphatic), arthritis (skeletal) and haematuria (renal) 10.  25 
 26 
Various social, environmental and biological risk factors determine the risk of TB contraction. Risks 27 
for infection and progression to disease are distinctly different; infection risk involves extrinsic 28 
factors including social and behavioural risks (alcohol, smoking and pollution), source 29 
infectiousness and proximity (including overcrowding and length of exposure), whereas risk of 30 
progression to disease is endogenous to the host 11. Immunosuppressive conditions accelerate 31 
progression to active disease, with HIV being especially potent 12. Impaired immune response as 32 
a result of malnutrition is also known to increase the risk of TB 13, whilst a strong socioeconomic 33 
association with the disease exists, with the poorest experiencing the greatest risk 14. Children 34 
also present an increased susceptibility to TB development, which is greater still before the age 35 
of 2 and after age 10 15. Other risk factors for progression to disease include diabetes, alcohol, 36 
smoking and indoor air pollution 11.  37 
 38 
Isoniazid and rifampicin form the basis of front-line treatment for TB 2, with both drugs included in 39 
the WHO Model List of Essential Medicines and Essential Medicines for Children. Isoniazid (BCS 40 
class I/III 16) is a pro-drug that requires activation by catalase-peroxidase enzyme (KatG), which 41 
is endogenous to MTB 17. The drug inhibits the synthesis of mycolic acids, essential components 42 
of the bacterial cell wall and at therapeutic doses is bactericidal against actively growing intra and 43 
extra cellular MTB 18. Rifampicin (BCS class II 19) also displays a bactericidal effect on MTB, by 44 
inhibition of transcription through high-affinity binding to the β-subunit of bacterial DNA-dependent 45 
RNA polymerase 20. Rifampicin is highly effective against TBM through its ability to readily diffuse 46 
into tissues, cells and bacteria 21. The tendency of rifampicin to degrade substantially when 47 
combined with isoniazid in acidic media is a well-recognised complication when considering 48 
combination of the two drugs in solid oral-dosage forms 22. 49 
 50 
The first-line recommended oral drug regimen for treatment of drug susceptible TB involves 51 
isoniazid, rifampicin, pyrazinamide and ethambutol for 2 months, followed by isoniazid and 52 
rifampicin for 4 months, with the regimen altering due to drug or multi-drug resistance 23. Treatment 53 
for extrapulmonary TB does not differ, except in some cases where duration of therapy is extended 54 
24. Recommended doses for treatment of children differ compared to adults. Fixed-dose 55 
combinations (FDCs) are recommended for TB treatment of both adults and children 23, however 56 
FDCs currently on the market do not correspond to appropriate doses for children 24. FDCs for TB 57 
treatment have not been shown to alter efficacy, drug resistance or adverse effects or events 58 
when compared to single-dose 24. Furthermore, whilst FDCs have not provided evidence for 59 
 
4 
improvement of treatment outcomes, their use simplifies TB therapy, with some evidence for an 1 
increase in patient satisfaction 25.  2 
 3 
Orally disintegrating tablets (ODTs) are an increasingly popular dosage form that improve 4 
compliance for patients with dysphagia, a difficulty swallowing, particularly prevalent in paediatric 5 
and geriatric populations, institutionalised and psychiatric patients and sufferers of nausea and 6 
vomiting 26. ODTs are designed to rapidly disintegrate in contact with saliva within the oral cavity, 7 
removing the need for swallowing and coadministration with water. Market studies have shown 8 
ODTs to be popular amongst patients, with over 50% preferring them to other dosage forms (such 9 
as regular tablets and liquids) and 70% of consumers declaring they would request ODTs from 10 
their physician 27. 11 
 12 
In order for a new generic formulation to be approved it needs to demonstrate bioequivalence with 13 
a reference branded product. A bioequivalent drug will display comparable bioavailability and thus 14 
in vivo performance (efficacy and safety) 28. Bioequivalence can be assumed in the absence of 15 
clinical trials, if there is no significant difference in the rate and extent to which the active 16 
pharmaceutical ingredient (API) becomes available within the systemic circulation, when 17 
compared with the reference product 29.  Bioequivalence testing may also be applied in the 18 
assessment of FDCs 28. For immediate release formulations bioequivalence can be determined 19 
by comparison of in vitro dissolution profiles using FDA recommended difference factor (f1) and 20 
similarity factor (f2) testing, for biowaiver applications 29. Comparison testing is not deemed 21 
necessary if test products display greater than 85% dissolution within 15 mins, given that the API 22 
falls within BCS class I or III (although class III carries stricter requirements) 28. The extension of 23 
biowaivers to BCS class II compounds is a topic of much discussion 30. 24 
 25 
Pharmacokinetic modelling and simulation has become an established tool over the past 20 years 26 
to predict drug pharmacokinetics in humans and assess the effect of intrinsic and extrinsic factors 27 
on drug exposure. Physiologically based pharmacokinetic (PBPK) models define tissues and 28 
organs as compartments, with parameters based upon decades of knowledge of body fluid 29 
dynamics. PBPK models consider ADME processes throughout all compartments to estimate the 30 
pharmacokinetic profile of a drug at a target tissue or organ 31. As such, PBPK models have 31 
become a powerful tool for the prediction of oral drug absorption through integration of common 32 
in vitro drug-specific information, alongside a variety of physiological descriptions of the population 33 
groups (e.g. age, weight, height, tissue perfusion, drug metabolising enzyme abundance and 34 
ontogeny) 32. PBPK modelling is often exploited for prediction of oral drug absorption and to study 35 
formulation changes 33 or FDCs 34. There is also an effort to apply PBPK modelling to predict the 36 
bioequivalence of new generic formulations with reference drugs 35. 37 
 38 
An FDC ODT for isoniazid and rifampicin could potentially improve patient compliance and be 39 
particularly beneficial in developing areas with little to no access to water. The use of a paediatric 40 
relevant dose would be valuable given the current lack of support and the widely reported and 41 
supported applicability of ODTs to enhance compliance in paediatric populations 36. Similarly, 42 
improved clinical outcomes from FDCs, due primarily to improved adherence as a result of 43 
reduced pill burden, are well documented 37.  44 
 45 
This work demonstrates the ability of PBPK modelling and clinical trial simulations to overcome 46 
the challenge of drug testing in paediatric populations. Specifically, this study focuses on the 47 
development of isoniazid and rifampicin single and FDC ODT formulations at paediatrically 48 
relevant doses. In vitro drug dissolution and permeability data was used to predict drug 49 
pharmacokinetics for in silico models, in order to investigate API bioequivalence between single 50 
and fixed-dose formulations. 51 
 52 
  53 
 
5 
Materials and Methods 1 
Materials 2 
Isoniazid and rifampicin were purchased from Molekula Ltd (UK). Pearlitol® Flash (mannitol-starch 3 
copolymer) was obtained from Roquette Pharma (France), whilst Avicel PH-102 micro-crystalline 4 
cellulose (MCC) and sodium stearyl fumarate (SSF) were purchased from FMC BioPolymer 5 
(USA). 6 
 7 
Biorelevant FaSSIF/FeSSIF/FaSSGF Instant Powder was purchased from biorelevant.com (UK). 8 
Sodium hydroxide, sodium chloride, sodium phosphate and glacial acetic acid for biorelevant 9 
media were obtained from Sigma-Aldrich (UK). Acetonitrile (ACN) and methanol (HPLC-grade) 10 
were obtained from Fisher Scientific (UK). 11 
 12 
For cell culture media DMEM was purchased from Lonza (UK), fetal bovine serum (FBS), 13 
gentamicin (10 mg/ml), Fungizone (amphotericin B 250 μg/ml), HBSS and penicillin/streptomycin 14 
(10,000 U/ml) were all purchased from Gibco (Thermo Fischer Scientific, UK). Trypsin-EDTA 15 
solution (0.25%) was procured from Sigma-Aldrich (UK). 16 
 17 
Tablet production 18 
Direct compression of tablets (500 mg) at a compaction force of 2.2 tons was performed on an 19 
Atlas T8 automatic press (SPECAC, UK), using a 13mm round, flat-faced die. Tablets were 20 
produced under ambient conditions. 21 
 22 
 23 
Disintegration testing 24 
Disintegration testing was performed in accordance with US pharmacopeia monograph ([701] 25 
disintegration). An Erweka ZT3, Appartebau, GMBH (Germany) was used as disintegration 26 
apparatus and 800 ml distilled water maintained at 37˚C was used as the disintegration media. 27 
Tablets were measured individually by placing in the basket rack and the time taken for the tablets 28 
to disintegrate without leaving any solid residue in the rack, recorded. Disintegration time was 29 
measured in triplicate. 30 
 31 
Friability 32 
Tablet friability was determined on 6 tablets using an F2 friability tester (Sotax, Switzerland). 33 
Tablets were placed inside the drum and rotated at 25 rpm for a total of 100 revolutions. Dust was 34 
removed pre and post testing to remove excess powder that would contribute to tablet mass. 35 
Friability was calculated and expressed as % tablet weight loss from initial tablet weight. 36 
 37 
Tablet hardness 38 
A Tablet Hardness Tester TBF1000 (Copley Scientific, UK) was used to measure the radial 39 
crushing strength (hardness) of tablets in triplicate.  40 
 41 
High performance liquid chromatography (HPLC) 42 
HPLC was performed on an Agilent 1260 series (Agilent Technologies, USA), comprising a 43 
quarternary pump, Infinity VWD and autosampler. Analysis was conducted on a reversed-phase 44 
Gemini C18, 150 x 4.6 mm, 110Å, 5μm column (Phenomenex, UK). Protocols were developed, 45 
calibrated and validated for both isoniazid and rifampicin alone and in combination. 46 
 47 
Separations were achieved using either (Type 1) H2O, 0.1% (v/v) TEA, 0.1% (v/v) TFA or ACN at 48 
different ratios as the mobile phase. Ascorbic acid (0.5 mg/ml) was included as an antioxidant to 49 
prevent rifampicin degradation 38. Isoniazid separation was performed with an isocratic mobile 50 
phase of H2O: ACN (90:10 v/v), a flow rate of 1 ml/min and a wavelength of 254 nm. Rifampicin 51 
 
6 
separation was achieved using an isocratic mobile phase of TFA: ACN (45:55 v/v), a flow rate of 1 
1 ml/min and a wavelength of 254 nm. Separation of isoniazid and rifampicin in combination 2 
required a mobile phase of TEA: ACN delivered at a gradient (95:5 to 20:80 v/v), with a flow rate 3 
of 1 ml/min and a wavelength of 254 nm. An injection volume of 20 μl was used throughout. 4 
 5 
HPLC method validation involved assessment of precision through intra-day variation, accuracy 6 
by multilevel recovery studies, instrument precision, linearity and limit of detection and 7 
quantification (LOD and LOQ). Stock solutions (1 mg/ml) of each drug were prepared in mobile 8 
phase from which dilutions and subsequently two-fold serial dilutions were prepared to form a 9 
calibration curve. 10 
 11 
Dissolution testing 12 
API dissolution from ODTs in 900 ml biorelevant media (FaSSIF/FeSSIF/FaSSGF instant powder, 13 
biorelevant.com, UK) was tested in both fasted state simulated intestinal fluid (FaSSIF) and fed 14 
state simulated intestinal fluid (FeSSIF), at pH 6.5 and 5 respectively and maintained at 37°C. An 15 
ERWEKA DT 600 USP 2 paddle apparatus (Germany) was used at a paddle speed of 50 rpm 39. 16 
5ml samples were taken over 2 h, replacing with 5 ml fresh media to simulate sink conditions. API 17 
dissolution was measured using HPLC and corrected for % dose dissolved.  18 
 19 
Cell culture 20 
Prior to seeding, cells were trypsinised (2.5 ml) from 75-cm2 cell culture flasks (Corning, USA) on 21 
which they had been grown (80% confluence), after washing with HBSS. Caco-2 cells (passage 22 
54-58) were seeded onto Transwell (Corning, USA) semi-permeable membrane supports (12-well, 23 
1.12 cm2, 0.4 μm pore size) at a density of 8x104 cells/cm2. Cells were maintained in Dulbecco’s 24 
modified Eagle’s minimal essential medium (DMEM) containing L-glutamine (4 mM) and glucose 25 
(4.5 mg/ml), and supplemented with (v/v) 10% fetal bovine serum, 1% penicillin/streptomycin, 1% 26 
non-essential amino acids, amphotericin B (0.5 μg/ml) and gentamicin (20 μg/ml).  Media was 27 
changed every 2-3 days and transwells cultured at 37°C, 5% CO2 for 21 days, after which transport 28 
studies were performed.  29 
 30 
 31 
Caco-2 transport studies 32 
Caco-2 cells were purchased from the European Collection of Authenticated Cell Cultures 33 
(ECACC) via Public Health England. Caco-2 monolayers were used for transport studies between 34 
21 and 24 days post-seeding. Drug absorption through Caco-2 monolayers was measured for 35 
isoniazid and rifampicin alone and in combination in both the apical to basolateral (A-B) and 36 
basolateral to apical (B-A) directions (n=3). Transport studies were carried out in DMEM (37°C) 37 
containing 10 mM HEPES (pH 7.4), with 0.5 ml and 1.5 ml in the A and B compartments, 38 
respectively. Samples of 100 μl were removed from the A side and 200 μl from the B side at time 39 
points over 2 h, replacing with fresh pre-warmed media (37°C) to mimic sink conditions. For mass 40 
balance, samples were taken from the donor compartments at t=0 and t=120 mins.  41 
 42 
Isoniazid was administered at a concentration of 20 μg/ml and rifampicin at a concentration of 30 43 
μg/ml. Concentrations used were comfortably within or below previously reported well tolerated 44 
concentration ranges for both isoniazid and rifampicin 40. Cultures were maintained at 37°C and 45 
5% CO2 throughout the experiment. Samples were analysed by HPLC and apparent permeability 46 
(Papp) values were calculated using equation: 47 
 48 
𝑃𝑎𝑝𝑝  =  (𝑑𝑄/𝑑𝑡)/(𝐶0 × 𝐴) 49 
 50 
Where dQ/dt is the mass transfer rate of the compound from the donor to the receiver 51 
compartment, C0 is the initial concentration in the donor chamber and A is the monolayer surface 52 





Clinical trials simulation 1 
The population-based clinical trials simulator Simcyp (V14) (Certara, USA) was used to simulate 2 
the plasma concentration of isoniazid and rifampicin from single API and FDC formulations. 3 
Default parameter values for creating a North European Caucasian population were selected 41.  4 
 5 
Compound data 6 
Physicochemical information for each API was collated from the literature used to develop 7 
compound files (Table 8).  Simulations were performed using a minimal-PBPK model. Where 8 
uncertainty arose regarding the precise value of compound data parameters, parameter 9 
estimation was conducted using the Parameter Estimation Module to optimize parameter values. 10 
The ADAM model 42 was assumed for all simulations and the dissolution profile for each 11 
formulation (single and FDC) in FaSSIF and FeSSIF was utilised. 12 
 13 
Clinical studies 14 
The optimization and validation of the PBPK model was conducted using clinical study results 15 
reported in healthy adult subjects. For isoniazid: study 1 included a total dose of 300 mg dosed to 16 
18 healthy volunteers (18-55 years old) 43; study 2 included a total dose of 300 mg dosed to 22 17 
healthy volunteers 44; study 3 included a total dose of 300 mg dosed to 20 healthy volunteers (23 18 
± 1.8 years old) 45; study 4 included a total dose of 300 mg dosed to 18 healthy volunteers (36.4 19 
± 10.6 years old) 46. Studies 1 and 2 were used for model development and studies 3 and 4 utilized 20 
for validation. 21 
 22 
For rifampicin:  study 1 included a total dose of 600 mg dosed to 18 healthy volunteers (18-55 23 
years old) 43; study 2 included a total dose of 600 mg dosed to 20 healthy volunteers (23 ± 1.8 24 
years old) 45; study 3 included a total dose of 600 mg dosed to 18 healthy volunteers (36.4 ± 10.6 25 
years old) 46; study 4 included a total dose of 600 mg dosed to 22 healthy volunteers 44. Studies 1 26 
and 2 were used for model development and studies 3 and 4 utilized for validation. 27 
 28 
Raw data from published human trial plasma concentration profiles was extracted using 29 
WebPlotDigitizer 3.10 47 and, where necessary, parameter estimation was conducted using the 30 
validation clinical datasets.  31 
 32 
Predictions of API plasma pharmacokinetic profiles were simulated following the oral 33 
administration of a single immediate release solid dosage form of 50mg (isoniazid) and 75 mg 34 
(rifampicin) dose over a 24 hr period. 35 
 36 
To assess the impact of ABCB1 active efflux on rifampicin fraction dose absorbed (fa), we 37 
conducted a local sensitivity analysis by varying ABCB1 active transport clearance (CLtrans) (0.1 38 
to 100 µL/min/pmol) and Papp (0.1-100 x10-6 cm/s), then assessing the resulting impact on fa. 39 
 40 
 41 
Statistical analysis 42 
GraphPad PRISM software version 6.01 (USA) was used for data analysis. Ordinary one-way 43 
ANOVA was used with Tukey’s multiple comparisons test to analyze data for tablet 44 
characterization. Unpaired two-tailed t-test was used to determine statistical differences between 45 
data sets for pharmacokinetic parameters.  46 
 47 
Differences between dissolution profiles of APIs in single dose (reference) and combination (test) 48 
were assessed using f1 and f2 difference and similarity factor testing, using the equations 48: 49 
 50 
















Where Rt and Tt are the % drug dissolved value at each time point for the reference and test 2 
product respectively and n is the number of time points. 3 
  4 
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Results and discussion 1 
ODT development 2 
An ODT formulation for rifampicin and isoniazid both alone and in combination was developed, 3 
with the requirement that tablets were mechanically robust whilst maintaining rapid disintegration. 4 
Round flat faced tablets (500 mg) were produced by direct compression. In order to isolate the 5 
effect of combination of APIs, the number of excipients used was kept at a minimum. The 6 
formulation consisted of API alongside Na stearyl fumerate (SSF, 0.5% w/w) as a lubricant and 7 
Pearlitol as a diluent. Compaction forces were applied at a range of 1-2 T, with hardness values 8 
acceptable (>60 N) from a compaction force of 1.2 T and above. Friability values at all compaction 9 
forces were high (>1%), with tablets compressed at and below 1.2 T unable to withstand friability 10 
testing. Disintegration times at all compaction forces were within 30 s (18-21 s), as recommended 11 
by the FDA for ODTs 49, with no significant effect (p>0.05) on disintegration with changes in 12 
compaction force. At 2 T compaction force tablet hardness peaked at 100.17 ± 7.97 N and friability 13 
dropped to 1.97%. Increasing SSF to 1.5% w/w ensured improved lubricant ability whilst 14 
maintaining high hardness and a low disintegration time.  15 
 16 
To combat high friability MCC was included as a binder 50. Addition of MCC up to 15% w/w 17 
increased hardness (p>0.01), compared to 5% and 10%, to 119.50 ± 3.90 N, whilst lowering 18 
friability and maintaining rapid disintegration. MCC has excellent binding properties due to its 19 
plastic deformation, maximising interparticulate bonding 50 and hydrogen bond formation between 20 
adjacent molecules 51, whilst mechanical interlocking has also been proposed as a mechanism 52. 21 
The high intraparticle porosity of MCC promotes rapid penetration of water through capillary action 22 
and is responsible for its ability to enhance disintegration 50. Raising compaction force to 2.2 T 23 
lowered tablet friability to 1.10-0.85 %, maintained rapid disintegration and raised hardness to as 24 
high as 151.17 ± 4.48 N. Formulation composition is shown in Table 1 and characterisation of 25 
formulations is shown in Table 2.  26 
 27 
 28 
HPLC protocol validation 29 
Linearity test solutions were prepared from stocks at six concentrations ranging from 100 to 1.5625 30 
μg/ml. Validation of protocols by intraday studies for isoniazid, rifampicin and isoniazid/rifampicin 31 
combination are shown in Table 3. Instrument precision, tested for by six consecutive injections 32 
of the same sample (100 μg/ml), ranged from 0.08% to 0.87%.  All protocols showed good method 33 
accuracy and precision. Method accuracy is demonstrated by multilevel recovery, ranging from 34 
100 μg/ml to 6.25 μg/ml. Accurate recovery was exhibited at each concentration for both APIs, 35 
ranging from 98.03% to 101.98%, with mean recovery values shown. Relative standard deviation 36 
(RSD) values representing intraday precision for isoniazid, rifampicin and isoniazid/rifampicin 37 
were low, ranging from 0.51 to 2.40 %, with mean values displayed. LOQ and LOD values for 38 
isoniazid and rifampicin alone were at or below 0.80 and 0.24 μg/ml, respectively. LOQ and LOD 39 
values for isoniazid in combination were lower still, whilst rifampicin in combination showed the 40 




Drug release from ODTs was tested in FaSSIF and FeSSIF media (Table 4). Rapid and complete 45 
isoniazid dissolution from single dose (99.24%) and FDC (100.65%) in FaSSIF (Figure 1) was 46 
observed. Difference testing showed dissolution profiles were equivalent (f1=14.17) however 47 
similarity testing indicated differences between both profiles (f2=32.79). Despite this, isoniazid 48 
dissolution exceeded 85% within 15 mins. In FeSSIF (Figure 2) similar drug release profiles for 49 
isoniazid are seen from both single and FDC formulations, with dissolution peaking at 100.12% 50 
and 101.52%, respectively and both formulations exceeding 85% dissolution by 5 mins. Values 51 
for f1 and f2 testing show no difference between the two dissolution profiles. 52 
 Rifampicin dissolution from single and FDC formulations in FaSSIF (Figure 3) was 53 
comparable based on f1 and f2 testing, with complete dissolution of 100.63% from single dose, 54 
whilst dissolution from FDC peaked at 91.91%. Dissolution profiles for rifampicin from single and 55 
FDC in FeSSIF (Figure 4) were deemed different, failing f1 and f2 testing. Rifampicin was rapidly 56 
 
10 
released from single dose, showing >85% dissolution by 5 mins, peaking at 98.26%, however in 1 
combination rifampicin release was retarded, with a maximum dissolution after 1 h of 85.32%. 2 
This observed drop in dissolution is likely a result of degradation, given the complete release seen 3 
from the single dose formulation and the well documented enhanced degradation of rifampicin in 4 
the presence of isoniazid under acidic conditions, in this instance pH 5. 5 
    6 
 7 
Permeability studies 8 
Transepithelial electrical resistance (TEER) values for Caco-2 cells over 21 days plateau from day 9 
18, showing a resistance of 1351.1 ± 88.6 Ω·cm2 by day 21 post-seeding. Isoniazid and rifampicin 10 
transport across Caco-2 monolayers alone and in combination was measured in A-B and B-A 11 
directions. Papp values are summarised for each drug and drug combination in Table 5. 12 
 13 
Isoniazid was readily absorbed across Caco-2 monolayers from both A-B and B-A directions, 14 
exhibiting an efflux ratio of 1.18 indicating passive diffusion. Similar permeability was displayed 15 
for isoniazid in combination with rifampicin, with an efflux ratio of 1.19. Rifampicin Papp values 16 
suggested active efflux of the compound, with efflux ratio values of 4.33 and 2.61 from single and 17 
combination respectively. Active efflux of rifampicin across Caco-2 monolayers has previously 18 
been indicated 53. 19 
 20 
 21 
Clinical trials simulation 22 
The initial simulation of the kinetics of isoniazid (derived from data presented in Table 8) were 23 
used to optimize the human jejenum effective permeability and volume of distribution at steady 24 
state (Peff and Vss, respectively) from clinical data sets 1 and 2 for each API. Peff describes a 25 
prediction of human absorption rate constants (ka), whereas Vss values describe a conversion 26 
factor (mass to concentration) and the tissue distribution of the API. Optimized Peff and Vss were 27 
estimated as 10.23 x10-4 cm/s and 0.63 L/kg. 28 
Use of passive permeability data (Table 5) to mechanistically model the absorption of rifampicin 29 
did not capture the absorption kinetics of rifampicin.  Very little data exists which supports the 30 
notion that rifampicin undergoes active transport, while the reported Fa of >0.9 54 would support 31 
the notion that no active efflux transporter pathways exist which impact upon the oral bioavailability 32 
of rifampicin.  However, to assess the impact of potential active efflux on rifampicin absorption, a 33 
sensitivity analysis was conducted where active intestinal efflux was attributed to ABCB1 (P-34 
glycoprotein) and the impact of variation in passive permeability (Papp) and active efflux transporter 35 
clearance (CLtrans) on rifampicin Fa was assessed (Figure 5). Assuming rifampicin is a highly 36 
permeable compound (human jejunum effective permeability, Peff, > 1x10-4 cm/s; Simcyp 37 
predicted Peff: 2.15 x10-4 cm/s) (BCS Class II), active efflux would only impact upon rifampicin Fa 38 
under conditions of high efflux (>10 µL/min/pmol).  However, for our measured Papp (0.137 x10-6 39 
cm/s) the resultant Peff is 0.19 x10-4 cm/s and would classify rifampicin as a low permeability 40 
compound. Furthermore, transporter clearance in excess of 1 µL/min/pmol would impact upon the 41 
overall Fa of rifampicin.  With this in mind, it was decided to utilise the default optimised rifampicin 42 
compound file (see Table 8) within Simcyp without alteration of the absorption kinetics. 43 
Subsequent validation of isoniazid and rifampicin using validation data sets 3 and 4 for each API 44 
was successful and generally centred around the mean simulated profiles and were within the 5th 45 
and 95th percentiles of the simulated profiles (see Figures 6 and 7). 46 
 47 
Simulations to predict the in vivo performance of ODTs in healthy volunteers were used to 48 
compare the bioavailability between single and FDC formulations under fasted and fed conditions, 49 
using the dissolution data. For isoniazid, the formulation state (single or combined) or dosing state 50 
(fasted or fed) had no statistically significant impact on pharmacokinetics (Figure 8 a and b). 51 
Isoniazid plasma concentrations reached a geometric mean Cmax of 0.70-0.74 ng/ml in all 52 




At the level of the small-intestine Fa for isoniazid correlated with dissolution profiles, showing no 1 
significant differences between single and combination formulations, with values of 0.98 ± 0.02 2 
and 0.97 ± 0.03 (fasted) and 0.99 ± 0.04 and 0.96 ± 0.05 (fed), respectively.  3 
 4 
Fa values for rifampicin were equivalent between formulation states at 0.94 in fasted subjects; 5 
likewise, no difference was seen in Fa for fed subjects, with values of 0.94 for both single and 6 
combination doses. These results imply that permeation across the intestinal epithelial 7 
membrane was not rate limiting, casting doubt on the ability of f1 and f2 factor testing in this 8 
instance to predict bioequivalence. Rifampicin plasma profiles similarly showed no statistically 9 
significant difference (p>0.05) in pharmacokinetic parameters between single and combination 10 
doses in fasted subjects (Figure 8c). Rifampicin plasma concentrations (Table 7) in FDCs 11 
(irrespective of dosing state) demonstrated higher AUCs (9.26 ng/ml.h) compared to single 12 
formulations (8.80 ng/ml.h). Furthermore, geometric mean Cmax was generally consistent across 13 
all formulations and conditions (1.22-1.24 ng/ml) with a tmax of 2.36-2.38 h. 14 
 15 
Bioavailability (F) for isoniazid in all cases was 1, whilst F values for rifampicin were 0.91. This 16 
may be related to the high Fa seen with both APIs. Bioavailability for rifampicin correlates well with 17 
reported values. Rifampicin is a CYP3A4 inducer 55 and it is likely that over a longer study period 18 
(i.e. multidose over a few weeks) F would drop to around 65-70%, as a result of increased 19 
metabolism 54. Furthermore, due to the inclusion of ascorbic acid as an antioxidant and since 20 
dissolution and degradation was not tested in simulated gastric fluid (at a lower pH), actual 21 
bioavailability values in vivo may differ. 22 





ODTs demonstrated satisfactory performance for hardness, friability and disintegration. 2 
Dissolution profile comparison between single and FDC formulations of isoniazid indicated 3 
bioequivalence regardless of dissolution media used and this was reinforced through PBPK 4 
modelling, with no difference in pharmacokinetic parameters. Comparable bioequivalence 5 
between single and FDC was not assumed for rifampicin from dissolution comparison in 6 
FeSSIF, with drug release falling by around 15%, likely as a result of rifampicin degradation. 7 
 8 
Clinical trial simulations reported no difference in isoniazid bioavailability between combination 9 
and single dose, despite isoniazid dissolution failing f2 testing in FaSSIF. Additionally, no food 10 
effect was seen. Notably also, the apparent decrease in rifampicin dissolution from FDCs in 11 
FeSSIF did not result in reduced bioavailability in fed subjects, whilst FDCs in fasted subjects 12 
similarly displayed bioequivalence with the single dose formulation, highlighting a failure in f1 13 
and f2 factor testing. 14 
 15 
PBPK modelling demonstrated that the bioavailability of either drug was unaltered as a result 16 
of combination with the other in these formulations. Rapid release isoniazid and rifampicin FDC 17 
ODTs thus may be a viable and attractive formulation prospect, whilst the framework used here 18 
could be employed in the development of more complex formulations. It should be noted that 19 
the focus for these investigations was on preformulation and initial dosage form development 20 
and therefore stability studies were not carried out. 21 
 22 
The application of PBPK modelling in this study demonstrated the ability of this technique to 23 
predict in vivo performance based on in vitro experimental work and thus overcome the 24 
difficulties in performing clinical trials in paediatric populations. Although PBPK modelling 25 
cannot replace real-world clinical testing in paediatrics, with further studies in real paediatric 26 
populations being required to confirm the results seen here, PBPK offers a  powerful tool to 27 
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Figure 1. Isoniazid (50 mg) dissolution profiles of single and FDC formulations in fasted state 
biorelevant media (900 ml, 37°C) from 500 mg ODTs. Dissolution performed using USP 2 paddle 




Figure 2. Isoniazid (50 mg) dissolution profiles of single and FDC formulations in fed state biorelevant 
media (900 ml, 37°C) from 500 mg ODTs. Dissolution performed using USP 2 paddle apparatus 





Figure 3. Rifampicin (75 mg) dissolution profiles of single and FDC formulations in fasted state 
biorelevant media (900 ml, 37°C) from 500 mg ODTs. Dissolution performed using USP 2 paddle 




Figure 4. Rifampicin (75 mg) dissolution profiles of single and FDC formulations in fed state 
biorelevant media (900 ml, 37°C) from 500 mg ODTs. Dissolution performed using USP 2 paddle 




Figure 5. Sensitivity analysis of rifampicin (Simcyp default compound) fraction dose absorbed (fa) when 
varying Papp (0.1-100 x10-6 cm/s) and intestinal active efflux (CLtrans) (0.1-100 µL/min/pmol ABCB1). Papp 




Figure 6. Simulated mean plasma profile after a 300 mg oral dose of isoniazid (solid black line). The 
corresponding observed data points are shown by red open circles. The grey lines represent the 5th 











Figure 7. Simulated mean plasma profile after a 600 mg oral dose of rifampicin (solid black line). The 
corresponding observed data points are shown by red (set 3) or green (set 4) open circles. The grey 
lines represent the 5th and 95th percentiles for the predicted values. All simulations were performed 













Figure 8. Simulated mean plasma profile after a 50 mg oral dose of isoniazid (a and b) and 75 mg oral 
dose of rifampicin (c and d) under fasted and fed conditions. Single API formulations indicated in black 
and fixed-dose combination in red.  Solid lines represent trial mean and dashed lines represent the 5th 














Table 1. ODT formulations for individual dose and FDC ODTs. Values for APIs and excipients are given 
as % w/w for 500mg tablets.  All formulations underwent compaction at 2.2 T with a 6 s dwell time. 
 Isoniazid (10%) Rifampicin (15%) 
Isoniazid + Rifampicin 
(10% + 15%) 
 F1 F2 F3 
Isoniazid 50  50 
Rifampicin  75 75 
Pearlitol 
Flash 
367.5 342.5 292.5 
SSF (1.5%) 7.5 7.5 7.5 
MCC (15%) 75 75 75 
 
 
Table 2. Individual and FDC ODT properties. All formulations underwent compaction at 2.2 T with a 6 
s dwell time. 
 Hardness (N) Porosity 
Disintegration Time 
(s) 
Friability (% weight 
loss) 
F1 95.50 ± 1.15 0.26 ± 0.01 22.67 ± 1.53 1.10 
F2 143.90 ± 15.47 0.25 ± 0.01 22.67 ± 1.15 0.86 






Table 3. HPLC method validation for detection of isoniazid and rifampicin both alone and in combination. Data for linearity (correlation coefficient), instrument 





% ± SD)  
Intraday precision 
(mean % RSD) 
LOD (µg /ml) LOQ (µg /ml) 
Correlation 
coefficient 
Isoniazid 0.08 99.53 ± 0.60 0.88 0.24 0.80 0.99997 
Rifampicin 0.13 100.33 ± 1.13 2.07 0.14 0.46 0.99994 
Isoniazid combination 0.27 99.64 ± 1.06 1.47 0.15 0.51 0.99996 




Table 4. Comparison of dissolution profiles for each compound from single and FDC formulations in 
FaSSIF and FeSSIF media, by difference factor f1 and similarity factor f2 testing. Dissolution profiles are 
considered similar if the f1 value is below 15 and the f2 value is above 50.   
Compound  >85% Dissolution ≤15 min f1 f2 
Isoniazid 
FaSSIF Yes 14.17 32.79 
FeSSIF Yes 3.78 65.30 
Rifampicin 
FaSSIF No 9.30 55.76 
FeSSIF No 15.55 44.82 
 
 
Table 5. Papp values for isoniazid and rifampicin alone and in combination in A-B and B-A directions, 
across Caco-2 monolayers at pH 7.4 in both compartments (mean ± SD, n=3) 
Compound Papp 10-6 cm s-1 Efflux Ratio 
 A-B B-A  
Isoniazid 16.37 ± 0.48 19.27 ± 0.32 1.18 
Rifampicin 1.37 ± 0.12 5.95 ± 0.42 4.33 
Isoniazid Combination 22.69 ± 1.21 26.98 ± 0.26 1.19 
Rifampicin Combination 2.14 ± 0.19 5.58 ± 0.50 2.61 
 
Table 6. Summary of pharmacokinetic parameters for isoniazid (50 mg) under fasted and fed conditions. Geometric mean (SD) reported for Cmax and median 
(range) for AUC and tmax  
 
  Isoniazid Fasted Isoniazid Fed 
Parameters Single Combined Single Combined 
AUC (ng/ml.h) 4.05 (3.14-7.10) 4.24 (3.13-7.41) 4.05 (3.14-7.10) 4.24 (3.13-7.42) 
Cmax (ng/ml) 0.74 (0.13) 0.70 (0.12) 0.74 (0.13) 0.70 (0.12) 




Table 7. Summary of pharmacokinetic parameters for rifampicin (75 mg) under fasted and fed conditions. Geometric mean (SD) reported for Cmax and median 
(range) for AUC and tmax  
  Rifampicin Fasted Rifampicin Fed 
Parameters Single Combined Single Combined 
AUC (ng/ml.h) 8.80 (6.63-13.63) 9.26 (6.61-13.50) 8.80 (6.63-13.63) 9.26 (6.61-13.50) 
Cmax (ng/ml) 1.24 (0.18) 1.22 (0.30) 1.24 (0.18) 1.22 (0.30) 
tmax (h) 2.38 (1.51-2.80) 2.38 (1.80-2.85) 2.38 (1.51-2.80) 2.36 (1.80-2.86) 
 
Table 8 Input parameter values and predicted PBPK values for simulation of pharmacokinetics of 
isoniazid and rifampicin. 
 
Parameter Isoniazid Rifampicin 
Type Monoprotic base Ampholyte 
MW 137.1 823 
LogP -0.7 4.01 
pKa 1.82 1.7,7.9 
fu 0.95 0.113 
Vss (L/kg)a Predicted PBPK/PE 0.42 (Full PBPK) 
B:P ratio 0.825 0.9 
Clpo (L/min) 12 8.75 
Peff (cms/s) PE 2.15 
MW: molecular weight; fu: plasma unbound fraction; Vss: steady-state volume of distribution; B:P ratio: 
blood-to-plasma ratio; CLpo: oral clearance; Peff: human effective permeability. a Vss was determined 
from calculation of tissue partitions coefficients within Simcyp or parameter estimated (PE).  
 
